Alpha Tau MedicalDRTS +4.67%32 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates DRTS with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 938 Biotechnology companies, Alpha Tau Medical ranks worse than 106609.7% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Alpha Tau Medical's EBITDA for the
three
months ended in Mar. 2026 was $-13.31 Mil. Alpha Tau Medical's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Alpha Tau Medical's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
Alpha Tau Medical (NAS:DRTS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Alpha Tau Medical EBITDA Margin % Related Terms
Alpha Tau Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRTS vs ORIC, OLMA, KURA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Alpha Tau Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical (DRTS) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #999999 out of 938 companies in the Biotechnology industry.
Is Alpha Tau Medical's EBITDA Margin % too high?
Alpha Tau Medical's current EBITDA Margin % is 0.00%. Based on the distribution chart, Alpha Tau Medical ranks #999999 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alpha Tau Medical has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's EBITDA Margin % compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #999999 out of 938 companies for EBITDA Margin %. This places Alpha Tau Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Alpha Tau Medical and its competitors. Alpha Tau Medical's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Alpha Tau Medical's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
32GF Score
Get the complete analysis for DRTS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
